A Global, Open-Label Extension Study for Participants(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Associated ConditionsPulmonary Hypertension
This is a medical research study to test an investigational form of a drug called treprostinil. 'Investigational' means that the way in which treprostinil is prepared and given to patients has not been approved by the United States FDA. Treprostinil has been approved by the FDA in other forms and is available by prescription under the following brand names: • Tyvaso (treprostinil) inhalation solution, for oral inhalation only • Orenitram (treprostinil) extended-release tablets, for oral use • Remodulin (treprostinil) injection, for subcutaneous (under the skin) or intravenous use The investigational form in this study is called LIQ861 and it delivers the drug to your lungs in a different way than the currently marketed product. In this study, LIQ861 will be inhaled using a hand-held device called a dry powder inhaler (DPI)in your current research study. Dose levels may be adjusted by the Study Doctor between 25 micrograms to 200 micrograms based on your PAH symptoms. The purpose of this research study is to evaluate the long-term safety of LIQ861 in patients with PAH.